Detection of human leukocyte antigen-A*32:01 in connection with determining drug reaction with eosinophilia and systemic symptoms (DRESS) and methods of treating bacterial infection in a subject with vancomycin-induced DRESS
Methods of detecting a human leukocyte antigen (HLA)-A*32:01 allele in a subject as disclosed are useful, for example, to determine whether the subject is at risk for developing or has vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Methods of treating bacterial infection in a subject with vancomycin-induced DRESS are also disclosed.
1. A method of detecting a human leukocyte antigen (HLA)-A*32:01 allele in a subject, comprising:
(a) obtaining a biological sample from the subject;
(b) detecting whether HLA-A*32:01 is present in the sample using a primer specific for a HLA-A*32 allele to determine whether the subject is at risk for developing or has vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) when HLA-A*32:01 is present in the sample, wherein the primer specific for HLA-A*32 is HLA 32-88F (SEQ ID NO: 1).
2. The method of claim 1 , wherein the subject has a bacterial infection.
3. The method of claim 2 , wherein the bacteria is an antibiotic-resistant gram-positive bacteria.
4. The method of claim 1 , wherein the biological sample is from a subject suspected of having DRESS.
5. The method of claim 4 , wherein the subject is receiving combination antibiotic treatment that includes vancomycin.
6. The method of claim 5 , wherein the subject is diagnosed as having vancomycin-induced DRESS when the presence of HLA-A*32:01 in the sample is detected.
7. The method of claim 6 , further comprising administering to the diagnosed subject an antibiotic treatment that excludes vancomycin.
8. The method of claim 1 , wherein the biological sample is from a subject in need of treatment with an antibiotic.
9. The method of claim 8 , and further comprising identifying the subject as being at risk for developing vancomycin DRESS when the presence of HLA-A*32:01 in the sample is detected.
10. The method of claim 9 , further comprising administering an antibiotic that is not vancomycin, teicoplanin, telavancin, or a glycopeptide antibiotic to the identified subject.
11. The method of claim 9 , further comprising administering dalbavancin to the identified subject.
12. The method of claim 1 , wherein sequenced-based typing is conducted to determine whether HLA-A*32:01 is present in the sample.
13. The method of claim 1 , wherein SNP2HLA is used to determine whether HLA-A*32:01 is present in the sample.
14. The method of claim 1 , and further comprising using an IFN-γ Enzyme-Linked ImmuneSpot assay.
15. The method of claim 1 , wherein a polymerase chain reaction assay is used to determine whether HLA-A*32:01 is present in the sample.
16. The method of claim 1 , and further using a second primer specific for HLA-A*32 that is HLA032R2 (SEQ ID NO: 2).
17. A kit comprising a primer specific for HLA-A*32, including HLA-A*32 is HLA 32-88F (SEQ ID NO: 1) and HLA-A*32 that is HLA032R2 (SEQ ID NO: 2).
18. A method of identifying risk of developing vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in a subject, comprising:
(a) obtaining a biological sample from the subject; and
(b) detecting whether HLA-A*32:01 is present in the sample using a primer mix containing one or both of HLA 32-88F (SEQ ID NO: 1) and HLA032R2 (SEQ ID NO: 2).
19. A method of diagnosing vancomycin DRESS in a subject and treating the subject for a bacterial infection, comprising:
(a) obtaining a biological sample from the subject;
(b) detecting whether HLA-A*32:01 is present in the sample using a primer mix containing one or both of HLA 32-88F (SEQ ID NO: 1) and HLA032R2 (SEQ ID NO: 2);
(c) diagnosing the subject with, or being at risk of developing, vancomycin DRESS when the presence of HLA-A*32:01 in the sample is detected; and
(d) administering an antibiotic that is not vancomycin to the diagnosed subject.